Literature DB >> 27449794

The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus.

Khairunnisa A Ghaffar, Nirmal Marasini, Ashwini K Giddam, Michael R Batzloff, Michael F Good, Mariusz Skwarczynski1, Istvan Toth2.   

Abstract

BACKGROUND: Group A streptococcus (GAS) is an exclusively human pathogenic bacteria. A delay in treatment of GAS infection often lead to severe diseases such as rheumatic heart disease which attributes to hundreds of thousands deaths annually. For the past few decades, the quest for a commercial GAS vaccine has been futile. Currently one of the most investigated strategies to develop vaccine against GAS includes the use of conserved epitopes from major virulent factor of GAS, M-protein.
METHODS: In this study, cationic liposomes of various sizes (70 nm to 1000 nm) were prepared with dimethyldioctadecylammonium bromide (DDAB) encapsulating lipopeptide bearing M-protein derived B-cell epitope (J14).
RESULTS: Smaller liposomes induced higher antibody titres, though the differences between groups were not statistically significant.
CONCLUSION: Nonetheless, all mice which were immunized with liposome-lipopeptide delivery system elicited high levels of systemic (IgG) and mucosal antibodies (IgA), which were discernably higher than those induced with the help of commercial adjuvant (cholera toxin B subunit). Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Peptide-based subunit vaccine; Streptococcus pyogenes; liposomes; mucosal immunity; self-adjuvanting.

Mesh:

Substances:

Year:  2016        PMID: 27449794     DOI: 10.2174/1573406412666160720093138

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  8 in total

Review 1.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

Review 2.  Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines.

Authors:  Aloysious Ssemaganda; Ashwini Kumar Giddam; Mehfuz Zaman; Mariusz Skwarczynski; Istvan Toth; Danielle I Stanisic; Michael F Good
Journal:  Front Immunol       Date:  2019-02-01       Impact factor: 7.561

Review 3.  Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus.

Authors:  Armira Azuar; Wanli Jin; Saori Mukaida; Waleed M Hussein; Istvan Toth; Mariusz Skwarczynski
Journal:  Vaccines (Basel)       Date:  2019-07-01

Review 4.  Application of nanotechnology in drug delivery systems for respiratory diseases (Review).

Authors:  Ming-Xin Luo; Shan Hua; Qi-Yun Shang
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

5.  Liposomes as Adjuvants and Vaccine Delivery Systems.

Authors:  D S Tretiakova; E L Vodovozova
Journal:  Biochem (Mosc) Suppl Ser A Membr Cell Biol       Date:  2022-02-14

6.  Poly(hydrophobic Amino Acids) and Liposomes for Delivery of Vaccine against Group A Streptococcus.

Authors:  Armira Azuar; Harrison Y R Madge; Jennifer C Boer; Jazmina L Gonzalez Cruz; Jingwen Wang; Zeinab G Khalil; Cyril Deceneux; Georgia Goodchild; Jieru Yang; Prashamsa Koirala; Waleed M Hussein; Robert J Capon; Magdalena Plebanski; Istvan Toth; Mariusz Skwarczynski
Journal:  Vaccines (Basel)       Date:  2022-07-29

7.  Cell-Penetrating Peptides-Based Liposomal Delivery System Enhanced Immunogenicity of Peptide-Based Vaccine against Group A Streptococcus.

Authors:  Jieru Yang; Farrhana Firdaus; Armira Azuar; Zeinab G Khalil; Nirmal Marasini; Robert J Capon; Waleed M Hussein; Istvan Toth; Mariusz Skwarczynski
Journal:  Vaccines (Basel)       Date:  2021-05-12

Review 8.  Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19.

Authors:  Jialu Huang; Yubo Ding; Jingwei Yao; Minghui Zhang; Yu Zhang; Zhuoyi Xie; Jianhong Zuo
Journal:  Vaccines (Basel)       Date:  2022-03-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.